Page last updated: 2024-08-18

pyrroles and Benign Mastocytoma

pyrroles has been researched along with Benign Mastocytoma in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Marycz, K; Serwotka-Suszczak, A; Sobierajska, P; Szymanski, D; Targonska, S; Wiglusz, RJ	1
Avery, AC; Burnett, RC; Duval, DL; Gustafson, DL; Halsey, CH; Rose, BJ; Thamm, DH; Wolf-Ringwall, A	1
Al-Sarraf, R; Johnson, CS; Malone, EK; Rassnick, KM; Ruslander, DM; Russell, DS; Trump, DL; Wakshlag, JJ	1

Trials

1 trial(s) available for pyrroles and Benign Mastocytoma

Article	Year
Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours. Veterinary and comparative oncology, 2010, Volume: 8, Issue:3 Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Calcitriol; Calcium Channel Agonists; Cell Line, Tumor; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Female; Imatinib Mesylate; Indoles; Lomustine; Male; Mastocytoma; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptors, Calcitriol; Skin Neoplasms; Treatment Outcome; Vinblastine	2010

Article

Year

Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours.

Veterinary and comparative oncology, 2010, Volume: 8, Issue:3

Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Calcitriol; Calcium Channel Agonists; Cell Line, Tumor; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Female; Imatinib Mesylate; Indoles; Lomustine; Male; Mastocytoma; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptors, Calcitriol; Skin Neoplasms; Treatment Outcome; Vinblastine

2010

Other Studies

2 other study(ies) available for pyrroles and Benign Mastocytoma

Article	Year
Synergistic Effect of Toceranib and Nanohydroxyapatite as a Drug Delivery Platform-Physicochemical Properties and In Vitro Studies on Mastocytoma Cells. International journal of molecular sciences, 2022, Feb-09, Volume: 23, Issue:4 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dog Diseases; Dogs; Drug Carriers; Drug Delivery Systems; Drug Synergism; Durapatite; Indoles; Mastocytoma; Nanoparticles; Protein Kinase Inhibitors; Pyrroles	2022
Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor. BMC veterinary research, 2014, May-06, Volume: 10 Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Dogs; Indoles; Mastocytoma; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; RNA, Messenger; Vinblastine	2014

Article

Year

Synergistic Effect of Toceranib and Nanohydroxyapatite as a Drug Delivery Platform-Physicochemical Properties and In Vitro Studies on Mastocytoma Cells.

International journal of molecular sciences, 2022, Feb-09, Volume: 23, Issue:4

Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dog Diseases; Dogs; Drug Carriers; Drug Delivery Systems; Drug Synergism; Durapatite; Indoles; Mastocytoma; Nanoparticles; Protein Kinase Inhibitors; Pyrroles

2022

Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.

BMC veterinary research, 2014, May-06, Volume: 10

Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Dogs; Indoles; Mastocytoma; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; RNA, Messenger; Vinblastine

2014